---
title: "Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Dosage"
description: "Formulary evidence on Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Dosage. Topics: Dose levels evaluated in the REVEAL Part A trials, Dose administered to the pivotal cohort, Dose in the ASPIRE trial adjusted for brain volume, Single administration, and 1 further topic. 5 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description/dosage"
published: "2026-11-15T20:23:41-05:00"
modified: "2026-11-15T20:23:41-05:00"
---

# Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### Dose levels evaluated in the REVEAL Part A trials

> “Two of the participants received the low dose (5.7×10¹⁴ vg) of TSHA-102 and four of the participants received the high dose (1×10¹⁵ vg) of TSHA-102.”

Source: [Taysha Gene Therapies healthcare professionals page](https://tayshagtx.com/healthcare-professionals/)

> “TSHA-102 Dose Level 1: 5.7×10¹⁴ total vector genomes (vg).”
> “TSHA-102 Dose Level 2: 1.0×10¹⁵ total vector genomes (vg)”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-2.1.2.10.1-2"></a>

### Dose administered to the pivotal cohort

> “TSHA-102 at Selected Dose (Dose Level 2): 1.0 × 10¹⁵ total vector genomes (vg)”
> “Participants receive a single intrathecal (IT) administration of TSHA-102 at Dose Level 2 (1.0 × 10¹⁵) (fully enrolled, 17 participants).”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-2.1.2.10.1-3"></a>

### Dose in the ASPIRE trial adjusted for brain volume

> “Participants receive a single intrathecal (IT) administration of TSHA-102 at 1.0 × 10¹⁵ total vector genomes (vg) adjusted for the participant's brain volume.”

Source: [ClinicalTrials.gov NCT07480564](https://clinicaltrials.gov/study/NCT07480564)

<a id="topic-2.1.2.10.1-4"></a>

### Single administration

> “TSHA-102 is a one-time intrathecal (IT) administration.”

Source: [ClinicalTrials.gov NCT05606614](https://clinicaltrials.gov/study/NCT05606614)

<a id="topic-2.1.2.10.1-5"></a>

### Dose escalation objective in the phase 1/2 trials

> “Evaluate two dose levels to, if possible, establish maximum administered dose (MAD) or maximum tolerated dose (MTD)”

Source: [Berry-Kravis et al. (2026a)](https://tayshagtx.com/wp-content/uploads/Safety-and-Efficacy-Results-from-the-REVEAL-Part-A-Phase-12-Trial-of-TSHA-102-in-Pediatric-and-AdolescentAdult-Cohort.pdf)

## Related pages
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Terms and abbreviations](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/terms-and-abbreviations.md)
- [Lonimecgene renparvovec (TSHA-102): Rett syndrome](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/executive-summary.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Product information and disease description](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/product-information-and-disease-description.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Clinical evidence](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/clinical-evidence.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: Economic information and modeling report](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/economics.md)
- [Lonimecgene renparvovec (TSHA-102) in Rett syndrome: References](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references) · [Markdown](https://www.evicenter.com/drugs/lonimecgene-renparvovec--rett-syndrome/references.md)
